Qun Li

USPTO Granted Patents = 51 (Patent Applications = 16)

CIPO Patents = 3 (Patent Applications = 15)

EPO Patents = 15 (Patent Applications = 24)

Average Co-Inventor Count = 3.2

ph-index = 10

Forward Citations = 415(Granted Patents)

Forward Citations (Not Self Cited) = 373(Oct 12, 2025)

Location History:

Huntington Beach, CA (US) (1993)
Newark, DE (US) (2006 - 2024)

Company Filing History:

Incyte Holdings Corporation

patents

4. 3 out of 86

Lexicon Pharmaceuticals, Inc.

B&w Tek Property, Inc.

patent

8. 1 out of 18

Prelude Therapeutics Incorporated

patents

9. 3 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1993-2025

Loading Chart...

51 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12459943 - Crystalline solid forms of a BET inhibitor (2025-11-04),

2. 12414953 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2025-09-16),

3. 12344596 - Solid forms of (S)-1-((2',6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof (2025-07-01),

4. 12247020 - Bipyrazole derivatives as JAK inhibitors (2025-03-11),

5. 12235211 - Apparatus and methods for controlled drug waste diversion detection (2025-02-25),

6. 12187730 - Salts of TAM inhibitors (2025-01-07),

7. 12043614 - Salts of a Pim kinase inhibitor (2024-07-23),

8. 12030882 - Crystalline solid forms of a bet inhibitor (2024-07-09),

9. 12024517 - Salts of an FGFR inhibitor (2024-07-02),

10. 11905275 - Bipyrazole derivatives as JAK inhibitors (2024-02-20),

11. 11866451 - Salts and crystalline forms of a PD-1/PD-L1 inhibitor (2024-01-09),

12. 11774352 - Apparatus and methods for controlled drug waste diversion detection (2023-10-03),

13. 11753406 - Salts of a PD-1/PD-L1 inhibitor (2023-09-12),

14. 11591318 - Bipyrazole derivatives as JAK inhibitors (2023-02-28),

15. 11512064 - Salts of an LSD1 inhibitor and processes for preparing the same (2022-11-29),

Title: Innovations and Contributions of Qun Li in Drug Identification

Introduction

Qun Li is an accomplished inventor based in Newark, DE, who holds an impressive portfolio of 47 patents. His groundbreaking work primarily focuses on innovations in drug identification and waste management. Through his inventions, he has contributed significantly to advancements in the pharmaceutical sector, particularly in enhancing drug safety and efficiency.

Latest Patents

One of Qun Li's latest inventions is an "Apparatus and methods for controlled drug waste diversion detection." This innovative technology employs a UV spectroscopy apparatus that features sample cells designed with optimized optical path lengths. The result is a measured maximum absorbance of the drug that is below the detection limits of the system, allowing for a complete unsaturated absorption spectrum to be revealed in the UV wavelength range from 230 nm to 400 nm. This full spectral analysis enhances drug identification specificity and accuracy in drug concentration verification.

Additionally, Qun Li has developed salts of TAM inhibitors, providing various salt forms of specific chemical compounds aimed at inhibiting TAM kinases. These inventions lay the groundwork for future processes and intermediates that are vital for drug development.

Career Highlights

Qun Li has worked with notable companies such as Incyte Corporation and Bwt Property, Inc., contributing his expertise and innovative ideas to their research and development efforts. His tenure at these organizations has allowed him to refine his skills and deepen his understanding of the pharmaceutical landscape.

Collaborations

In his career, Qun Li has collaborated with esteemed colleagues including Zhongjiang Jia and Sean Xiaolu Wang. These partnerships have enabled him to enhance his research capabilities and drive forward impactful innovations within the field.

Conclusion

Qun Li's dedication to innovation in drug identification and his remarkable portfolio of patents reflect his significant contributions to the pharmaceutical industry. His work continues to inspire advancements that prioritize drug safety and efficacy, ensuring better healthcare outcomes for society.

This text is generated by artificial intelligence and may not be accurate.